MARKET

MTVA

MTVA

MetaVia Inc
NASDAQ
1.620
-0.040
-2.41%
After Hours: 1.620 0 0.00% 19:30 09/14 EDT
OPEN
1.640
PREV CLOSE
1.660
HIGH
1.870
LOW
1.600
VOLUME
76.76K
TURNOVER
--
52 WEEK HIGH
19.03
52 WEEK LOW
0.9661
MARKET CAP
10.67M
P/E (TTM)
-0.4002
1D
5D
1M
3M
1Y
5Y
1D
Analyst Maintains Buy Rating on MetaVia (MTVA) with Unchanged $8 Price Target, Citing Strong Early Obesity Data for DA-1726
TipRanks · 4d ago
MetaVia Highlights DA-1726 Preclinical Data for Obesity Program
TipRanks · 5d ago
MetaVia reports results from DA-1726-derived radioactivity study
TipRanks · 5d ago
Weekly Report: what happened at MTVA last week (0831-0904)?
Weekly Report · 09/07 09:44
Weekly Report: what happened at MTVA last week (0824-0828)?
Weekly Report · 08/31 09:49
Weekly Report: what happened at MTVA last week (0817-0821)?
Weekly Report · 08/24 09:49
Weekly Report: what happened at MTVA last week (0810-0814)?
Weekly Report · 08/17 09:50
MetaVia (MTVA): Buy Rating Reiterated as DA-1726 Nears Key 4Q26 Data; $20 Price Target Reaffirmed
TipRanks · 08/10 10:45
More
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Webull offers MetaVia Inc stock information, including NASDAQ: MTVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTVA stock methods without spending real money on the virtual paper trading platform.